Last reviewed · How we verify
NCT04722627
Study of AT-752 in Healthy Subjects
Phase 1 trial testing AT-752 in Dengue in 65 participants. Completed in 14 November 2021.
14 November 2021
Quick facts
| Lead sponsor | Atea Pharmaceuticals, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 65 |
| Start date | 9 March 2021 |
| Primary completion | 14 November 2021 |
| Estimated completion | 14 November 2021 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- AT-752 — full drug profile →
- Placebo
Conditions studied
- Dengue — all drugs for Dengue →
Sponsor
Atea Pharmaceuticals, Inc. — full company profile →
Who can join
Adults 18 to 65, any sex, with Dengue. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-752 in healthy subjects
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04722627
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of AT-752
Trials testing the same drug.
- NCT05466240 — Study of AT-752 in Patients With Dengue Infection · Phase 2 · terminated
- NCT05366439 — Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model · Phase 1 · terminated
Other recruiting trials for Dengue
Currently open trials in the same condition.
- NCT07501793 — Demographic Characteristics of TAK-003 Dengue Vaccine Recipients in Vietnam · active not recruiting
- NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting
- NCT07007585 — Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus Infection · recruiting
- NCT06894901 — Impact of IIT-SIT on Dengue Clusters · NA · recruiting
- NCT07158190 — Evaluation of T-cell Responses After Vaccination With the Attenuated Tetravalent Dengue Vaccine (Takeda). · active not recruiting
Other Atea Pharmaceuticals, Inc. trials
Trials by the same sponsor.
- NCT07272889 — Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG) · Phase 1 · completed
- NCT07007806 — Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir · Phase 1 · completed
- NCT06921941 — Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin · Phase 1 · completed
- NCT06356194 — Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir · Phase 1 · completed
- NCT06204679 — Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04722627 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Atea Pharmaceuticals, Inc.
- Last refreshed: 17 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04722627.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing